The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects.

@article{Breuer2008TheTM,
  title={The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects.},
  author={Megan E. Breuer and Johnny S.W. Chan and Ronald S. Oosting and Lucianne Groenink and S Mechiel Korte and Una Campbell and Rudy Schreiber and Taleen Hanania and Eelke M S Snoeren and Maria Waldinger and Berend Olivier},
  journal={European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology},
  year={2008},
  volume={18 12},
  pages={908-16}
}
Current antidepressants have a delayed onset of action and disturbing side effects, including inhibition of sexual behavior. It is hypothesized that novel drugs, hitting multiple disease-relevant targets, may yield a new generation of superior antidepressants. One such approach is simultaneous inhibition of serotonin, norepinephrine and dopamine transporters. We tested the triple uptake inhibitor (TUI), DOV 216,303 (5, 10 and 20 mg/kg) after 1, 7 and 14 days administration in the olfactory… CONTINUE READING